BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28842676)

  • 1. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis.
    Wu D; Duan C; Chen L; Chen S
    Sci Rep; 2017 Aug; 7(1):9509. PubMed ID: 28842676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.
    Thomas X; Elhamri M; Raffoux E; Renneville A; Pautas C; de Botton S; de Revel T; Reman O; Terré C; Gardin C; Chelghoum Y; Boissel N; Quesnel B; Hicheri Y; Bourhis JH; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
    Blood; 2011 Aug; 118(7):1754-62. PubMed ID: 21690555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
    Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
    BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
    Tangchitpianvit K; Rattarittamrong E; Chai-Adisaksopha C; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Tantiworawit A; Norasetthada L
    Hematology; 2021 Dec; 26(1):355-364. PubMed ID: 33853503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.
    Zhou JH; Lin HQ; Shen Q; Hu LN; Li GQ; Sun XF; Zhang XY
    Curr Med Sci; 2018 Feb; 38(1):51-57. PubMed ID: 30074151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.
    Löwenberg B
    Blood; 2013 Jan; 121(1):26-8. PubMed ID: 23287624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia.
    Azevedo MC; Velloso ED; Buccheri V; Chamone DA; Dorlhiac-Llacer PE
    Braz J Med Biol Res; 2015 Feb; 48(2):178-85. PubMed ID: 25517921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal dose and schedule of consolidation in AML: is there a standard?
    Schiffer CA
    Best Pract Res Clin Haematol; 2014; 27(3-4):259-64. PubMed ID: 25455275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose cytarabine: a review.
    Bolwell BJ; Cassileth PA; Gale RP
    Leukemia; 1988 May; 2(5):253-60. PubMed ID: 3287015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
    Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
    Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
    J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
    Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H
    Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytarabine dose for acute myeloid leukemia.
    Löwenberg B; Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Biemond BJ; Gratwohl A; de Greef GE; Verdonck LF; Schaafsma MR; Gregor M; Theobald M; Schanz U; Maertens J; Ossenkoppele GJ;
    N Engl J Med; 2011 Mar; 364(11):1027-36. PubMed ID: 21410371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.
    Ye L; Gao L; Cheng Q; Guo F; He L; Yuan T; Zhu M; Ma Y; Pan M; Chu X; Ding M; Yu G
    Medicine (Baltimore); 2021 Jan; 100(3):e24273. PubMed ID: 33546048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
    Zhang W; Ding Y; Wu H; Chen Y; Lu H; Chen C; Fu J; Wang W; Liang A; Zou S
    Medicine (Baltimore); 2014 Dec; 93(27):e134. PubMed ID: 25501050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.
    Kern W; Estey EH
    Cancer; 2006 Jul; 107(1):116-24. PubMed ID: 16721819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.